Atezolizumab (Tecentriq) Concentrate from United States
Atezolizumab (Tecentriq) is a humanized monoclonal antibody targeting PD-L1, used in immunotherapy for bladder cancer and other malignancies. It is supplied as a concentrate for infusion in measured-dose vials for retail sale, meeting the criteria for tariff item 3002.15.00. This product directly regulates immunological processes through checkpoint inhibition.
Duty Rate — United States → Canada
0%
Import Tips
• Confirm the product is in retail packaging with measured doses to avoid reclassification
• Provide documentation showing the product's immunological mechanism for customs verification
• Check if a Clinical Trial Application or NOC is needed from Health Canada